Iversen T, Skjeldestad F E
Int J Gynaecol Obstet. 1985 Apr;23(2):95-9. doi: 10.1016/0020-7292(85)90050-5.
Two-hundred and ninety-three patients without a previous vaginal delivery were randomized to intracervical/extra-amniotic application of 0.5 mg prostaglandin E2 (PGE2) or to gel only. Of the patients who received PGE2, 18.7% were admitted before the next morning due to spontaneous abortion, bleeding or pains. No other side-effect was observed. A statistically significant dilatation of the cervical canal was found in the prostaglandin group. Thirty percent of the treated patients did not need further dilatation of the cervix 25.4% were non-responders to PGE2 and 7.7% were hyper-responders. The number of uterine perforations, pelvic inflammatory disease (PID) or retained pregnancy products were not influenced by the pretreatment with PGE2.
293例未曾经阴道分娩的患者被随机分为两组，一组宫颈内/羊膜外应用0.5毫克前列腺素E2（PGE2），另一组仅使用凝胶。接受PGE2治疗的患者中，18.7%因自然流产、出血或疼痛于次日早晨前入院。未观察到其他副作用。前列腺素组宫颈管扩张有统计学意义。30%接受治疗的患者无需进一步扩宫，25.4%对PGE2无反应，7.7%为高反应者。子宫穿孔、盆腔炎（PID）或妊娠物残留的数量不受PGE2预处理的影响。
